The COVID-19 pandemic hasn’t slowed down the Food and Drug Administration’s approval of new cancer treatments. Here are the latest arrivals:

  • Jelmyto (mitomycin) for upper urinary tract cancer
  • Koselugo (selumetinib) for pediatric neurofibromatosis (nerve tumors)
  • Pemazyre (pemigatinib) for cholangiocarcinoma (bile duct cancer)
  • Retevmo (selpercatinib) for non-small-cell lung cancer and thyroid cancers
  • Sarclisa (isatuximab) for multiple myeloma
  • Tabrecta (capmatinib) for non-small-cell lung cancer
  • Trodelvy (sacituzumab govitecan) for metastatic triple-negative breast cancer
  • Tukysa (tucatinib) for advanced or metastatic HER2-positive breast cancer.